Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Prostate Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


14 drugs have received FDA approval for Prostate Cancer . (R)-BICALUTAMIDE, 223, Abiraterone Acetate, Cabazitaxel, Degarelix, Denosumab, Docetaxel, Enzalutamide, Goserelin Acetate, Hydroxyflutamide, JNJ-56021927, Leuprolide Acetate, Mitoxantrone Hydrochloride and Nilutamide
430 drugs have a clinical trial registered for Prostate Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 3206 clinical trials for Prostate Cancer,
1613 of which have one or more drug interventions,
1593 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 62 Cell Line Models for Prostate Cancer.

Source: COSMIC
(see details)

Chemistry


There are 10144 Compounds which have been tested in Prostate Cancer , 6042 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Prostate Cancer:
Prostatic Neoplasms
Prostatic Neoplasms, Castration-Resistant

The following terms have been mapped from cancer.gov to Prostate Cancer:
Prostate cancer in patients receiving androgen deprivation therapy.These uses are approved for the Prolia brand of denosumab
Prostate cancer that has metastasized (spread to other parts of the body) in men whose cancer is castration resistant (has not responded to treatments that lower testosterone levels) and who have already been treated with other chemotherapy
Prostate cancer that has metastasized (spread to other parts of the body). It is used in patients who have had surgery to remove the testicles (orchiectomy)
Prostate cancer that has metastasized (spread to other parts of the body). It is used with a type of drug called a luteinizing hormone-releasing hormone agonist
Prostate cancer that has metastasized (spread to other parts of the body). It is used:In patients whose disease is castration resistant (has not responded to treatments that lower testosterone levels)
Prostate cancer that has metastasized in men whose cancer is hormone-refractory (does not respond to hormone treatment)
Prostate cancer that has not metastasized (spread to other parts of the body) and is castration resistant (has not responded to treatments that lower testosterone levels)
Prostate cancer that is advanced
Prostate cancer that is castration resistant (has not responded to treatments that lower testosterone levels)
Prostate cancer that is castration resistant (has not responded to treatments that lower testosterone levels). It is used in patients whose disease has metastasized (spread) to the bones and is causing symptoms but has not spread to other organs
Prostate cancer that may be locally advanced or has metastasized (spread to other parts of the body). It is used with a type of drug called a luteinizing hormone-releasing hormone agonist
Prostate cancer. It is used as palliative treatment in advanced disease that is hormone-refractory (does not respond to hormone treatment)
Prostate cancer. It is used with flutamide and radiation therapy in localized prostate cancer. It is also used as palliative treatment in advanced prostate cancer